Literature DB >> 17016793

Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma.

C M Lo1, S T Fan, C L Liu, S C Chan, I O-L Ng, J Wong.   

Abstract

BACKGROUND: Hypothetical studies that favour living donor liver transplantation (LDLT) for early hepatocellular carcinoma (HCC) assumed a comparable outcome after LDLT and deceased donor liver transplantation (DDLT). The aim of this study was to compare the outcome after LDLT with that after DDLT, and to identify factors that might account for any differences.
METHODS: The study included 60 patients who met the radiological Milan or University of California at San Francisco (UCSF) criteria and underwent LDLT (43 patients) or DDLT (17).
RESULTS: The LDLT group had fewer incidental tumours and a lower rate of pretransplant transarterial chemoembolization but a higher rate of salvage transplantation. Waiting time was shorter and graft weight to standard liver weight (GW : SLW) ratio was lower in this group. The perioperative course, and histopathological tumour size, number, grade and stage were comparable. Median follow-up was 33 (range 4-120) months. The cumulative 5-year recurrence rate was 29 per cent in the LDLT group and 0 per cent in the DDLT group (P = 0.029). A GW : SLW ratio of 0.6 or less, salvage transplantation, three or more tumour nodules, microscopic vascular invasion, and pathological stage beyond the Milan or UCSF criteria were significant confounding risk factors. Multivariable analysis identified salvage transplantation (relative risk 5.16 (95 per cent confidence interval (c.i.) 1.48 to 18.02); P = 0.010) and pathological stage beyond the UCSF criteria (relative risk 4.10 (95 per cent c.i. 1.02 to 16.48); P = 0.047) as independent predictors of recurrence.
CONCLUSION: Despite standard radiological selection criteria based on number and size, patients who underwent LDLT for HCC had more recurrence because of selection bias for other clinical characteristics. Copyright 2006 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2007        PMID: 17016793     DOI: 10.1002/bjs.5528

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  66 in total

1.  Incidence of Occult Intrahepatic Metastasis in Hepatocellular Carcinoma Treated With Transplantation Corresponds to Early Recurrence Rates After Partial Hepatectomy.

Authors:  David D Aufhauser; Eran Sadot; Douglas R Murken; Kevin Eddinger; Maarouf Hoteit; Peter L Abt; David S Goldberg; Ronald P DeMatteo; Matthew H Levine
Journal:  Ann Surg       Date:  2018-05       Impact factor: 12.969

2.  Living donor liver transplantation does not increase tumor recurrence of hepatocellular carcinoma compared to deceased donor transplantation.

Authors:  Guang-Qin Xiao; Jiu-Lin Song; Shu Shen; Jia-Yin Yang; Lu-Nan Yan
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

3.  Living donor liver transplantation for hepatocellular carcinoma: defining criteria to extend indications.

Authors:  Irinel Popescu
Journal:  Dig Dis Sci       Date:  2008-07-16       Impact factor: 3.199

4.  Living-donor or deceased-donor liver transplantation for hepatic carcinoma: a case-matched comparison.

Authors:  Ping Wan; Jian-Jun Zhang; Qi-Gen Li; Ning Xu; Ming Zhang; Xiao-Song Chen; Long-Zhi Han; Qiang Xia
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

5.  Inappropriate inferences from registry data: Pitfalls of inaccurate data handling?

Authors:  Rahul Kakodkar
Journal:  Indian J Gastroenterol       Date:  2017-03-30

6.  Survival analysis of high-intensity focused ultrasound ablation in patients with small hepatocellular carcinoma.

Authors:  Tan To Cheung; Sheung Tat Fan; Ferdinand S K Chu; Caroline R Jenkins; Kenneth S H Chok; Simon H Y Tsang; Wing Chiu Dai; Albert C Y Chan; See Ching Chan; Thomas C C Yau; Ronnie T P Poon; Chung Mau Lo
Journal:  HPB (Oxford)       Date:  2012-12-04       Impact factor: 3.647

Review 7.  Living donor liver transplantation for hepatocellular cancer: an (almost) exclusive Eastern procedure?

Authors:  Rafael S Pinheiro; Daniel R Waisberg; Lucas S Nacif; Vinicius Rocha-Santos; Rubens M Arantes; Liliana Ducatti; Rodrigo B Martino; Quirino Lai; Wellington Andraus; Luiz A C D'Albuquerque
Journal:  Transl Gastroenterol Hepatol       Date:  2017-08-29

8.  Good longterm survival after primary living donor liver transplantation for solitary hepatocellular carcinomas up to 8 cm in diameter.

Authors:  Wing Chiu Dai; See Ching Chan; Kenneth S H Chok; Tan To Cheung; William W Sharr; Albert C Y Chan; Simon H Y Tsang; James Y Y Fung; Ronnie T P Poon; Sheung Tat Fan; Chung Mau Lo
Journal:  HPB (Oxford)       Date:  2014-01-28       Impact factor: 3.647

Review 9.  Liver transplantation for hepatocellular carcinoma.

Authors:  Sudeep Tanwar; Shahid A Khan; Vijay Paul Bob Grover; Catherine Gwilt; Belinda Smith; Ashley Brown
Journal:  World J Gastroenterol       Date:  2009-11-28       Impact factor: 5.742

Review 10.  Impact of non-oncological factors on tumor recurrence after liver transplantation in hepatocellular carcinoma patients.

Authors:  Xiang-Qian Gu; Wei-Ping Zheng; Da-Hong Teng; Ji-San Sun; Hong Zheng
Journal:  World J Gastroenterol       Date:  2016-03-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.